Emerging Company Profile

Entrada: Moving cell-penetrating DMD therapy into clinic with $116M series B

Emerging Company Profile: 5AM-incubated intracellular biologics company makes DMD its top priority

5AM-incubated intracellular biologics company Entrada is making Duchenne muscular dystrophy its top priority.

With $116 million to deploy from its new series B crossover round, Entrada has concluded that DMD is its top